An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia

Objective: We conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. Method: Ten clozapine-treated subjects received aripiprazole augmentation; eight completed the 6-week trial and two ended at week 4. Eighty percent were male, the mean age was 38.7 ± 8.9 years and the mean clozapine dose was 455 ± 83 mg daily. Results: There was a significant decrease in weight (P ¼ 0.003), body mass index (P ¼ 0.004), fasting total serum cholesterol (P ¼ 0.002) and total triglycerides (P ¼ 0.04) comparing baseline to study endpoint. There was no significant change in total Positive and Negative Syndrome Scale scores. Conclusion: This combination may be useful for clozapine-associated medical morbidity and must be studied in placebo-controlled doubleblind randomized trials to determine efficacy and safety.